Related Experiment Video
Updated: May 5, 2026
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
[ALK rearrangement in non-small cell lung cancer]
Gaspard Naulleau1, Gary Birsen1, Audrey Mansuet-Lupo2
1Service de Pneumologie, Unité d'Oncologie Thoracique, Hôpital Cochin, AP-HP. Centre, Université Paris Cité, Paris, France.
Abstract:
The discovery of ALK gene rearrangement in 3 to 5% of non-small cell lung carcinomas has revolutionized our understanding and therapeutic approach of these cancers. This oncogenic driver is associated with specific clinical and biological features is associated with specific clinical and biological features, mainly affecting young and never-smoker patients, with a particular tropism for brain metastases. The development of ALK tyrosine kinase inhibitors has transformed patient outcomes, with remarkable efficacy of latest-generation molecules, particularly in controlling brain metastases. However, the emergence of complex resistance mechanisms, whether ALK-dependent or ALK-independent, remains a major challenge. The comprehensive understanding of these resistance mechanisms now guides the development of next-generation inhibitors and innovative therapeutic strategies, paving the way for increasingly personalized precision medicine.
Insights
Anaplastic Lymphoma Kinase (ALK) gene rearrangements drive specific lung cancers, particularly in young, non-smoking patients. Targeted therapies show promise, but overcoming resistance is key for personalized medicine.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Anaplastic Lymphoma Kinase (ALK) gene rearrangements are identified in 3-5% of non-small cell lung carcinomas (NSCLC).
- ALK-positive NSCLC often presents in younger, never-smoker patients and shows a propensity for brain metastases.
- The advent of ALK tyrosine kinase inhibitors (TKIs) has significantly improved patient outcomes.
Purpose of the Study:
- To review the impact of ALK gene rearrangements in NSCLC.
- To discuss the efficacy of ALK inhibitors, especially in managing brain metastases.
- To explore the challenges posed by resistance mechanisms and future therapeutic directions.
Main Methods:
- Literature review of ALK-driven NSCLC.
- Analysis of clinical and biological features of ALK-positive NSCLC.
- Examination of TKI efficacy and resistance patterns.
Main Results:
- ALK rearrangements define a distinct subset of NSCLC with unique clinical characteristics.
- First- and later-generation ALK inhibitors have demonstrated substantial clinical benefit.
- Brain metastases control is a notable success of ALK-targeted therapies.
- Emergence of ALK-dependent and independent resistance mechanisms poses a significant clinical hurdle.
Conclusions:
- Understanding ALK alterations has transformed NSCLC treatment paradigms.
- Next-generation inhibitors and novel strategies are being developed to overcome resistance.
- Continued research into resistance mechanisms is crucial for advancing personalized precision medicine in NSCLC.
More Related Videos
Related Concept Videos
![[3,3] Sigmatropic Rearrangement of 1,5-Dienes: Cope Rearrangement](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2Ffiles%2Fmedia%2Fscience-education%2Fscience-education-thumbs%2F12422.jpg&w=3840&q=75)
01:21[3,3] Sigmatropic Rearrangement of 1,5-Dienes: Cope Rearrangement
![[3,3] Sigmatropic Rearrangement of Allyl Vinyl Ethers: Claisen Rearrangement](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2Ffiles%2Fmedia%2Fscience-education%2Fscience-education-thumbs%2F13097.jpg&w=3840&q=75)
01:24[3,3] Sigmatropic Rearrangement of Allyl Vinyl Ethers: Claisen Rearrangement